Ra Pharmaceuticals (NASDAQ:RARX) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

A number of other research firms have also recently weighed in on RARX. Zacks Investment Research upgraded shares of Ra Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Tuesday, August 14th. ValuEngine upgraded shares of Ra Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, September 27th. Raymond James upgraded shares of Ra Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $28.00 price target on the stock in a report on Wednesday, October 10th. Credit Suisse Group set a $25.00 price target on shares of Ra Pharmaceuticals and gave the company a “buy” rating in a report on Friday, October 19th. Finally, BMO Capital Markets set a $21.00 price target on shares of Ra Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, November 8th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Ra Pharmaceuticals presently has an average rating of “Buy” and an average price target of $21.50.

NASDAQ RARX opened at $16.46 on Friday. The stock has a market cap of $524.52 million, a price-to-earnings ratio of -6.83 and a beta of 2.11. Ra Pharmaceuticals has a one year low of $4.78 and a one year high of $19.43.

Ra Pharmaceuticals (NASDAQ:RARX) last posted its earnings results on Wednesday, November 7th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.02). As a group, equities research analysts expect that Ra Pharmaceuticals will post -2.11 earnings per share for the current fiscal year.

Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of Ra Pharmaceuticals by 9.1% in the 3rd quarter. Vanguard Group Inc. now owns 739,337 shares of the company’s stock valued at $13,374,000 after buying an additional 61,929 shares in the last quarter. TIAA CREF Investment Management LLC boosted its holdings in shares of Ra Pharmaceuticals by 289.7% in the 3rd quarter. TIAA CREF Investment Management LLC now owns 280,761 shares of the company’s stock valued at $5,079,000 after buying an additional 208,720 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Ra Pharmaceuticals in the 3rd quarter valued at about $1,415,000. Algert Global LLC bought a new stake in shares of Ra Pharmaceuticals in the 3rd quarter valued at about $1,394,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of Ra Pharmaceuticals by 116.0% in the 3rd quarter. Renaissance Technologies LLC now owns 145,800 shares of the company’s stock valued at $2,638,000 after buying an additional 78,300 shares in the last quarter. Institutional investors and hedge funds own 74.74% of the company’s stock.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Featured Story: Consumer behavior in bull markets

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.